Cargando…
Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
PURPOSE: There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) patients. The objective of this study is to investigate the potential of (18)F-FDG-PET/ CT to predict mortality in IPF. METHODS: A total of 113 IPF patients (93 males, 20 females, mean age ± SD: 70 ± 9 years) we...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978900/ https://www.ncbi.nlm.nih.gov/pubmed/29335764 http://dx.doi.org/10.1007/s00259-017-3917-8 |
_version_ | 1783327578772209664 |
---|---|
author | Win, Thida Screaton, Nicholas J. Porter, Joanna C. Ganeshan, Balaji Maher, Toby M. Fraioli, Francesco Endozo, Raymondo Shortman, Robert I. Hurrell, Lynn Holman, Beverley F. Thielemans, Kris Rashidnasab, Alaleh Hutton, Brian F. Lukey, Pauline T. Flynn, Aiden Ell, Peter J. Groves, Ashley M. |
author_facet | Win, Thida Screaton, Nicholas J. Porter, Joanna C. Ganeshan, Balaji Maher, Toby M. Fraioli, Francesco Endozo, Raymondo Shortman, Robert I. Hurrell, Lynn Holman, Beverley F. Thielemans, Kris Rashidnasab, Alaleh Hutton, Brian F. Lukey, Pauline T. Flynn, Aiden Ell, Peter J. Groves, Ashley M. |
author_sort | Win, Thida |
collection | PubMed |
description | PURPOSE: There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) patients. The objective of this study is to investigate the potential of (18)F-FDG-PET/ CT to predict mortality in IPF. METHODS: A total of 113 IPF patients (93 males, 20 females, mean age ± SD: 70 ± 9 years) were prospectively recruited for (18)F-FDG-PET/CT. The overall maximum pulmonary uptake of (18)F-FDG (SUV(max)), the minimum pulmonary uptake or background lung activity (SUV(min)), and target-to-background (SUV(max)/ SUV(min)) ratio (TBR) were quantified using routine region-of-interest analysis. Kaplan–Meier analysis was used to identify associations of PET measurements with mortality. We also compared PET associations with IPF mortality with the established GAP (gender age and physiology) scoring system. Cox analysis assessed the independence of the significant PET measurement(s) from GAP score. We investigated synergisms between pulmonary (18)F-FDG-PET measurements and GAP score for risk stratification in IPF patients. RESULTS: During a mean follow-up of 29 months, there were 54 deaths. The mean TBR ± SD was 5.6 ± 2.7. Mortality was associated with high pulmonary TBR (p = 0.009), low forced vital capacity (FVC; p = 0.001), low transfer factor (TLCO; p < 0.001), high GAP index (p = 0.003), and high GAP stage (p = 0.003). Stepwise forward-Wald–Cox analysis revealed that the pulmonary TBR was independent of GAP classification (p = 0.010). The median survival in IPF patients with a TBR < 4.9 was 71 months, whilst in those with TBR > 4.9 was 24 months. Combining PET data with GAP data (“PET modified GAP score”) refined the ability to predict mortality. CONCLUSIONS: A high pulmonary TBR is independently associated with increased risk of mortality in IPF patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-017-3917-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5978900 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-59789002018-06-21 Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) Win, Thida Screaton, Nicholas J. Porter, Joanna C. Ganeshan, Balaji Maher, Toby M. Fraioli, Francesco Endozo, Raymondo Shortman, Robert I. Hurrell, Lynn Holman, Beverley F. Thielemans, Kris Rashidnasab, Alaleh Hutton, Brian F. Lukey, Pauline T. Flynn, Aiden Ell, Peter J. Groves, Ashley M. Eur J Nucl Med Mol Imaging Original Article PURPOSE: There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) patients. The objective of this study is to investigate the potential of (18)F-FDG-PET/ CT to predict mortality in IPF. METHODS: A total of 113 IPF patients (93 males, 20 females, mean age ± SD: 70 ± 9 years) were prospectively recruited for (18)F-FDG-PET/CT. The overall maximum pulmonary uptake of (18)F-FDG (SUV(max)), the minimum pulmonary uptake or background lung activity (SUV(min)), and target-to-background (SUV(max)/ SUV(min)) ratio (TBR) were quantified using routine region-of-interest analysis. Kaplan–Meier analysis was used to identify associations of PET measurements with mortality. We also compared PET associations with IPF mortality with the established GAP (gender age and physiology) scoring system. Cox analysis assessed the independence of the significant PET measurement(s) from GAP score. We investigated synergisms between pulmonary (18)F-FDG-PET measurements and GAP score for risk stratification in IPF patients. RESULTS: During a mean follow-up of 29 months, there were 54 deaths. The mean TBR ± SD was 5.6 ± 2.7. Mortality was associated with high pulmonary TBR (p = 0.009), low forced vital capacity (FVC; p = 0.001), low transfer factor (TLCO; p < 0.001), high GAP index (p = 0.003), and high GAP stage (p = 0.003). Stepwise forward-Wald–Cox analysis revealed that the pulmonary TBR was independent of GAP classification (p = 0.010). The median survival in IPF patients with a TBR < 4.9 was 71 months, whilst in those with TBR > 4.9 was 24 months. Combining PET data with GAP data (“PET modified GAP score”) refined the ability to predict mortality. CONCLUSIONS: A high pulmonary TBR is independently associated with increased risk of mortality in IPF patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-017-3917-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-01-16 2018 /pmc/articles/PMC5978900/ /pubmed/29335764 http://dx.doi.org/10.1007/s00259-017-3917-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Win, Thida Screaton, Nicholas J. Porter, Joanna C. Ganeshan, Balaji Maher, Toby M. Fraioli, Francesco Endozo, Raymondo Shortman, Robert I. Hurrell, Lynn Holman, Beverley F. Thielemans, Kris Rashidnasab, Alaleh Hutton, Brian F. Lukey, Pauline T. Flynn, Aiden Ell, Peter J. Groves, Ashley M. Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) |
title | Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) |
title_full | Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) |
title_fullStr | Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) |
title_full_unstemmed | Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) |
title_short | Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF) |
title_sort | pulmonary (18)f-fdg uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (ipf) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978900/ https://www.ncbi.nlm.nih.gov/pubmed/29335764 http://dx.doi.org/10.1007/s00259-017-3917-8 |
work_keys_str_mv | AT winthida pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT screatonnicholasj pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT porterjoannac pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT ganeshanbalaji pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT mahertobym pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT fraiolifrancesco pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT endozoraymondo pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT shortmanroberti pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT hurrelllynn pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT holmanbeverleyf pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT thielemanskris pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT rashidnasabalaleh pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT huttonbrianf pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT lukeypaulinet pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT flynnaiden pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT ellpeterj pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf AT grovesashleym pulmonary18ffdguptakehelpsrefinecurrentriskstratificationinidiopathicpulmonaryfibrosisipf |